- Home
- BMEA vs VFL Comparison
BMEA vs VFL Comparison
Compare BMEA & VFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- VFL
- Stock Information
- Founded
- BMEA 2017
- VFL 1993
- Country
- BMEA United States
- VFL United States
- Employees
- BMEA N/A
- VFL N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- VFL Finance/Investors Services
- Sector
- BMEA Health Care
- VFL Finance
- Exchange
- BMEA Nasdaq
- VFL Nasdaq
- Market Cap
- BMEA 114.3M
- VFL 116.3M
- IPO Year
- BMEA 2021
- VFL N/A
- Fundamental
- Price
- BMEA $1.93
- VFL $10.27
- Analyst Decision
- BMEA Strong Buy
- VFL
- Analyst Count
- BMEA 10
- VFL 0
- Target Price
- BMEA $15.70
- VFL N/A
- AVG Volume (30 Days)
- BMEA 559.5K
- VFL 38.0K
- Earning Date
- BMEA 10-28-2025
- VFL 01-01-0001
- Dividend Yield
- BMEA N/A
- VFL 4.16%
- EPS Growth
- BMEA N/A
- VFL N/A
- EPS
- BMEA N/A
- VFL N/A
- Revenue
- BMEA N/A
- VFL N/A
- Revenue This Year
- BMEA N/A
- VFL N/A
- Revenue Next Year
- BMEA N/A
- VFL N/A
- P/E Ratio
- BMEA N/A
- VFL N/A
- Revenue Growth
- BMEA N/A
- VFL N/A
- 52 Week Low
- BMEA $1.29
- VFL $7.93
- 52 Week High
- BMEA $13.07
- VFL $10.77
- Technical
- Relative Strength Index (RSI)
- BMEA 55.47
- VFL 86.90
- Support Level
- BMEA $1.77
- VFL $9.53
- Resistance Level
- BMEA $2.08
- VFL $10.31
- Average True Range (ATR)
- BMEA 0.11
- VFL 0.08
- MACD
- BMEA 0.01
- VFL 0.08
- Stochastic Oscillator
- BMEA 51.61
- VFL 95.00
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About VFL abrdn National Municipal Income Fund
Delaware Investments Natl Muni Income is a closed-end investment fund. The Fund seeks to provide current income exempt from regular federal income tax consistent with the preservation of capital. The company's product portfolio includes Mutual funds, Exchange-traded funds, Private markets, Delaware Funds by Macquarie Premier Models, Managed accounts, Closed-end funds, and Variable Insurance Products.